Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guska is a biotech startup developing next-generation cancer immunotherapies based on engineered synthetic RNA oncolytic viruses. Their proprietary platform uses AI-driven design to enhance tumor specificity and safety, including genetic attenuation to prevent reversion to virulence. The company has demonstrated promising preclinical results in patient-derived xenograft models for pancreatic and lung cancers. They are expanding their pipeline and seeking partnerships as they approach IND-enabling studies, with their next major milestone expected after securing a seed round in Q2 2026.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guska.